Neurocrine Biosciences, Inc.
NBIX announced today that it has initiated a second Phase II
clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound,
NBI-98854. The design of this second Phase II study is a randomized,
double-blind, placebo controlled, cross-over trial, using a within-subject
comparison for safety and efficacy evaluation.
This 32 patient study will
assess once-daily NBI-98854 over a two week dosing period.
The primary endpoint of the study will be a comparison of placebo vs. active
scores on the Abnormal Involuntary Movement Scale.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in